<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527059</url>
  </required_header>
  <id_info>
    <org_study_id>LEV1068</org_study_id>
    <nct_id>NCT00527059</nct_id>
  </id_info>
  <brief_title>Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure</brief_title>
  <official_title>Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of levosimendan infusion, in addition to&#xD;
      standard therapy,on renal function in patients with Acute Heart Failure,compared with&#xD;
      standard therapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The term &quot;cardiorenal syndrome&quot; has been applied to the presence or development of a renal&#xD;
      dysfunction in HF patients and may be the major precipitant of decompensation and cause for&#xD;
      admission in these patients. The renal hypoperfusion that occurs with cardiac injury can lead&#xD;
      to sodium and water retention and activation of the renin-angiotensin-aldosterone system and&#xD;
      neurohormonal pathways with resultant deleterious effects on the myocardium. A vicious cycle&#xD;
      may then ensue and be associated with increased cardiovascular complications. In this regard,&#xD;
      renal dysfunction is of a functional nature and thus means to intervene with this vicious&#xD;
      cycle need to be sought.&#xD;
&#xD;
      Several studies already demonstrated the deleterious effects of renal dysfunction on&#xD;
      prognosis in patients with HF due to chronic left ventricular dysfunction.&#xD;
&#xD;
      Levosimendan increases myocardial contractility without significant changes in the&#xD;
      intracellular calcium ion and cyclic adenosine monophosphate concentrations and does not&#xD;
      enhance myocardial oxygen demand. By its action on the potassium channels this drug also&#xD;
      dilates the coronary and peripheral arteries and exerts an anti-ischemic,anti-stunning&#xD;
      effect. To date, the effects of levosimendan on renal function in patients with worsening&#xD;
      chronic HF, remain unknown.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: GFR measured by inulin Clearance.</measure>
    <time_frame>0, 24. 48 and 72 hours after Levosimendan infusion starting</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints: •Other renal function measures: BUN, albumin, urine volume, sodium excretion and plasma sodium, and cystatin. •Hemodynamic parameters: PCWP, PAP, cardiac output, HR, BP, renal blood flow.</measure>
    <time_frame>0,1,24,48 and 72 hours after Levosimendan infusion started</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Heart Failure</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with acute heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard therapy for heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan in addition to standard therapy</intervention_name>
    <description>intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spironolactone, beta-blockers,ecc</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  an ejection fraction (EF) 40% by transthoracic echocardiogram,&#xD;
&#xD;
          -  a baseline pulmonary capillary wedge pressure (PCWP) 20 mm Hg&#xD;
&#xD;
          -  a MDRD (Modification of Diet Renal Disease) score &gt; 30 and &lt; 60&#xD;
&#xD;
          -  and a standard therapy for HF that should include angiotensin converting enzyme&#xD;
             inhibitors, angiotensin receptor blockers, aldosterone blocking agents&#xD;
             (spironolactone) and beta-blockers, unless contraindicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients receiving other oral or i.v. inotropes,&#xD;
&#xD;
          -  oral or i.v. diuretics&#xD;
&#xD;
          -  or receiving nitroglycerine or nitroprusside,&#xD;
&#xD;
          -  patients with systolic blood pressure &lt;110 mmHg,&#xD;
&#xD;
          -  mechanical ventilation,&#xD;
&#xD;
          -  anticipated survival &lt;30 days,&#xD;
&#xD;
          -  absence of thoracic windows for echocardiography,&#xD;
&#xD;
          -  acute coronary syndromes,&#xD;
&#xD;
          -  sustained ventricular tachycardia or ventricular fibrillation,&#xD;
&#xD;
          -  documented renal artery stenosis, requiring dialysis,&#xD;
&#xD;
          -  requiring admission primarily for concurrent morbidity,&#xD;
&#xD;
          -  severe aortic or mitral regurgitation,&#xD;
&#xD;
          -  left ventricular failure primarily from uncorrected obstructive valvular disease,&#xD;
             hypertrophic obstructive cardiomyopathy, restrictive/obstructive cardiomyopathy,&#xD;
&#xD;
          -  uncorrected thyroid disease,&#xD;
&#xD;
          -  known amyloid cardiomyopathy&#xD;
&#xD;
          -  or known malfunctioning artificial heart valve.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Fedele, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiovascular, Respiratory and Morphological Sciences, University of Rome La Sapienza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Fedele, professor</last_name>
    <phone>0039-0649979020</phone>
    <email>francesco.fedele@uniroma1.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiovascular, Respiratory and Morphological Sciences, University of Rome La Sapienza</name>
      <address>
        <city>Rome, viale del Policlinico 155</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>September 7, 2007</last_update_submitted>
  <last_update_submitted_qc>September 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2007</last_update_posted>
  <keyword>Cardiorenal syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

